Supplementary Figure 5 from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma

Sun Min Lim; Seong-san Kang; Dong Kwon Kim; Soo‐Hwan Lee; Chun‐Bong Synn; Sujeong Baek; Seung M. Yang; Yu J. Han; Mi H. Kim; Heekyung Han; Kwangmin Na; Young T. Kim; Mi Ran Yun; Jae Hwan Kim; Youngseon Byeon; Young S. Kim; Jii Bum Lee; Min Hee Hong; Joshua C. Curtin; Bharvin Patel; Isabelle Bergiers; Kyoung‐Ho Pyo; Byoung Chul Cho

doi:10.1158/2767-9764.26318616

Abstract

This figure shows the selection of cell lines used for in vitro evaluation of the effects of amivantamab on the protein and surface levels EGFR, MET, LDHA and SLC16A3.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lim et al. (2024) studied this question.

synapsesocial.com/papers/68e60020b6db643587594198 https://doi.org/10.1158/2767-9764.26318616

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure 5 from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma

Abstract

Discussion

Cite This Study

Supplementary Figure 5 from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma

Abstract

Discussion

Cite This Study

Keep reading

Keep reading